LEADER 00996nam--2200349---450- 001 990001551220203316 005 20050720123514.0 035 $a000155122 035 $aUSA01000155122 035 $a(ALEPH)000155122USA01 035 $a000155122 100 $a20040401d1964----km-y0itay0103----ba 101 $ager 102 $aDE 105 $a||||||||001yy 200 1 $aUber han dlun, Gesprad und Erzaslung$fJohann Jakob, Engel 210 $aStuttgart$cMeblevirosre$d1964 215 $a155 p.$d19 cm 410 0$12001 454 1$12001 461 1$1001-------$12001 700 1$aENGEL,$bJohann Jakob$0199620 801 0$aIT$bsalbc$gISBD 912 $a990001551220203316 951 $aVII.2.A. 435(II T D 43/3)$b33497 L.M.$cII T 959 $aBK 969 $aUMA 979 $aSIAV9$b10$c20040401$lUSA01$h1018 979 $aPATRY$b90$c20040406$lUSA01$h1747 979 $aCOPAT7$b90$c20050720$lUSA01$h1235 996 $aUber han dlun, Gesprad und Erzaslung$9941031 997 $aUNISA LEADER 01838nam2 22003251i 450 001 RML0280154 005 20231121125730.0 100 $a20121121d1976 ||||0itac50 ba 101 | $agrc$alat 102 $abe 181 1$6z01$ai $bxxxe 182 1$6z01$an 200 1 $a˜95: Tou œen hagiois patros hemon Ioannou, tou Damaskenou, monachou, kai presbyterou Hierosolymon, ta euriskomena panta$dSancti patris nostri Joannis Damasceni, monachi, et presbyteri Hierosolymitani, opera omnia quae exstant$fcura et studio Michaelis Lequien$gvariorum curis adaucta, nempe, Andr. Gallandii, Ang. Maii, Wegelini 210 $aTurnhout $cBrepols $d1976 215 $a1592 col.$d29 cm 300 $aTesto latino a fronte. -In testa al front.: Saeculum 8., annus 756. -Rist. anast. dell'ed.: Parisiis : Migne, 1860 461 1$1001RML0279685$12001 $aPatrologiae cursus completus omnium ss. Patrum, doctorum scriptorumque ecclesiasticorum, sive Latinorum sive Graecorum$faccurante J.P. Migne. Series graeca 510 1 $aSancti patris nostri Joannis Damasceni, monachi , et presbyteri Hierosolymitani, opera omnia quae exstant$9RML0337280 700 1$aJohannes$b, Damascenus$3RMLV172213$0714504 702 1$aMai$b, Angelo$3RMLV180223 702 1$aGallandi$b, Andrea$3RMLV180423 702 1$aLe Quien$b, Michel$3RMLV180424 801 3$aIT$bIT-01$c20121121 850 $aIT-FR0017 899 $aBiblioteca umanistica Giorgio Aprea$bFR0017 912 $aRML0280154 950 2$aBiblioteca umanistica Giorgio Aprea$d 52CIS P.G.95$e 52VM 0000498795 VM barcode:00028894. - Inventario:18361 MAGVM$fB $h20041110$i20121204 977 $a 52 996 $aEn hagiois patros hemon Ioannou, tou Damaskenou, monachou, kai presbyterou Hierosolymon, ta euriskomena panta$93626541 997 $aUNICAS LEADER 05988nam 22007335 450 001 9911021141303321 005 20250818130248.0 010 $a3-032-03862-6 024 7 $a10.1007/978-3-032-03862-3 035 $a(CKB)40378275000041 035 $a(MiAaPQ)EBC32265671 035 $a(Au-PeEL)EBL32265671 035 $a(DE-He213)978-3-032-03862-3 035 $a(OCoLC)1535966801 035 $a(EXLCZ)9940378275000041 100 $a20250818d2025 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach /$fedited by Nima Rezaei 205 $a1st ed. 2025. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2025. 215 $a1 online resource (1318 pages) 225 1 $aInterdisciplinary Cancer Research,$x2731-457X ;$v25 311 08$a3-032-03861-8 327 $aTargeting Mitochondria in Cancer Immunotherapy; Promises and Pitfalls -- Immunotherapy in Oncology: A Comprehensive Overview from a Pathological Perspective -- Cancer Treatments through Immunological Pathways: A Great Hope for Every Cancer Type and Every Patient? -- Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances -- Immune Checkpoint Inhibitors: Novel Therapies and Targets -- Advancing Cancer Immune Cell Therapies via Engineered iPSC-based Strategies -- CAR NK/CAR T cells: Emerging Immunotherapy of Cancer -- Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies -- The Power of Imaging Techniques in CAR T-Cell Therapy Enhancement: Revolutionizing Cancer Treatment -- Discovery of T cell Epitopes for Cancer Immunotherapy -- Dendritic Cells in Cancer Immunotherapy: Current State and Future Prospects -- Tumor Microenvironment Role in Cancer Immunotherapy Response -- T-cell Responses During Cancer Immunotherapy Through the Use of CT, MRI, and PET -- Nanotechnology for Cancer Research (Diagnosis & Therapy): Recent Progress and Future Prospects -- Nanotechnology and Cancer Therapy Strategies -- Nanomedicine based Cancer Immunotherapy -- Applications of Nanocarrier Systems in Cancer Treatment -- Nanoformulations in Cancer Theranostics -- The Role of Noble Metal Nanomaterials in Cancer Therapy -- Synthetic and Natural Drug Nanodelivery Systems Used in Oncology Treatment -- Nanoparticles Loaded with Cytotoxic Agents: A Therapeutic Alternative against Cancer -- Advancements in Nanocarrier-Mediated Drug Delivery: Precision Strategies for Targeted Therapeutics and Improved Treatment Outcomes -- Vesicular Nanosystem as a Promising Platform for the Management of Cancer -- Nanoscale Metal-Organic Frameworks for Cancer-Targeted Therapy and Molecular Imaging -- Theranostic Properties of Iron Oxide Nanoparticles and Their Reprograming Properties on Tumor-associated Macrophages -- Composition of Proapoptotic Montmorillonite-Cytochrome C Nanoplates with High Anticancer Cytotoxicity: Monolayer Adsorption Approach -- Nanomaterials as Modulators of Non-apoptotic Regulated Cell Death Modes: Novel Options in Cancer Treatment. 330 $aThe ?Cancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach? is the twenty fifth volume of the ?Interdisciplinary Cancer Research? series, publishes comprehensive volume on cancer immunotherapy and nanobiotechnology. The volume starts with chapters on targeting mitochondria in cancer immunotherapy, immunotherapy in oncology, and cancer treatments through immunological pathways. Immune checkpoint inhibitors as well as engineered iPSC-based strategies are explained in other chapters after discussion on cancer stem cells. CAR NK, CAR T cells, and DC therapy are the subjects of the following chapters. Then tumor microenviroment in response to immunotherapy and T-cell responses during cancer immunotherapy through the use of imaging are explained. The second half of the volume is focused on application of nanobiotechnology in cancer, starting with general chapters on nanotechnology for cancer research, nanotechnology and cancer therapy strategies, nanomedicine based cancer immunotherapy, applications of nanocarrier systems in cancer treatment, and nanoformulations in cancer theranostics. Then the role of metal nanomaterials in cancer therapy, synthetic drug nanodelivery systems, nanoparticles loaded with cytotoxic agents, nanocarrier-mediated drug delivery, vesicular nanosystem, and nanoscale metal-organic frameworks for cancer-targeted therapy are explained. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer immunotherapy and nanobiotechnology. 410 0$aInterdisciplinary Cancer Research,$x2731-457X ;$v25 606 $aCancer 606 $aCancer$xTreatment 606 $aStem cells 606 $aCytology 606 $aMedical genetics 606 $aImmunology 606 $aCancer Biology 606 $aCancer Therapy 606 $aCancer Stem Cells 606 $aCell Biology 606 $aMedical Genetics 606 $aImmunology 615 0$aCancer. 615 0$aCancer$xTreatment. 615 0$aStem cells. 615 0$aCytology. 615 0$aMedical genetics. 615 0$aImmunology. 615 14$aCancer Biology. 615 24$aCancer Therapy. 615 24$aCancer Stem Cells. 615 24$aCell Biology. 615 24$aMedical Genetics. 615 24$aImmunology. 676 $a571.978 676 $a616.994 700 $aRezaei$b Nima$0913363 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911021141303321 996 $aCancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach$94430799 997 $aUNINA